Welcome to our searchable resource and literature collection on safer supply and related topics.

Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.

Created in collaboration with peers and providers
Guidelines | 2018
About prescribers, About PWUD, Workplace, Peer/PWLLE program involvement
Commentary | 2021
Policy/Regulatory, Decriminalization/legalization, About prescribers, Hallucinogens/psychedelics
Handout | 2021
Safer supply, Illegal drugs, Diversion

BC safe suply interim guidance for safe supply/COVID-19 risk mitigation during the pandemic

Guidelines | 2022
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Rural/remote, Substitution/OAT, Carries/take-home doses
Guidelines | 2017
Clinical guidance, Policy/Regulatory, About prescribers, SCS/OPS
The cost-effectiveness of Canada's only supervised injection facility has not been rigorously evaluated.
Original research | 2008
Evidence base, Advocacy, Illegal drugs, Social benefits, SCS/OPS
This study estimated retention in buprenorphine and methadone treatment and its relationship with person, treatment and prescriber characteristics.
Original research | 2021
About prescribers, Substitution/OAT
WHO observed that the social fallout from COVID-19 hits women even harder (economic insecurity, single parenthood, violence, barriers to accessing services, etc.).
Lit review | 2020
Equity, Sex/Gender
Commentary | 2021
Mortality, Policy/Regulatory, Safer supply, Equity, Barriers and enablers, Housing, Rural/remote, Small/medium cities, Stigma
Evidence synthesis
Original research | 2018
Overdose, Mortality, Evidence base, Policy/Regulatory, Advocacy, Legal system/law enforcement, Illegal drugs, Indigenous, Sex/Gender
This paper presents the work of an ongoing international collaboration of organizations advocating legal regulation and some of the knowledge translation tools used to educate and engage the public on
Commentary | 2020
Slide deck | 2020
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment
The purpose of this paper is to conduct a cost-effectiveness and cost-benefit analysis of this SIF using secondary data gathered and analysed in 2008.
Original research | 2010
Evidence base, Advocacy, Social benefits, SCS/OPS
This study explored the acceptability of, and barriers and facilitators to, embedding a pilot physical healthcare service within a community-based drug service in the United Kingdom (Bristol, England)
Original research | 2022
Wrap-around services, Social services, Barriers and enablers, Stigma
Describes a city-wide COVID-19 care model for the homeless population
Case study | 2020
Harm reduction, Social services, Housing
Response to Tyndall 2020 (A safer drug supply…)
Letter | 2020
Hesitancy of prescribers , About prescribers
This study examines patient correlates of buprenorphine retention and whether an integrated, interdisciplinary treatment model (buprenorphine and behavioral health) is associated with higher odds of b
Original research | 2021
About prescribers, Outcomes, Substitution/OAT, Mental health
In Canada, restrictions on BUP-NX prescribing were relaxed in 2016, which may have had an effect on rates of diversion and non-prescribed use.
Original research | 2022
Hesitancy of prescribers , About PWUD, Substitution/OAT, Diversion
The current study examined how COVID-19 has impacted substance use supply and use characteristics among a national cohort of PWUD in Canada.
Original research | 2021
Overdose, Evidence base, Harm reduction, Policy/Regulatory, Safer supply, Advocacy, About PWUD

Refine Your Search